According to a press release from WW, with this acquisition, the company will be able to provide the support needed to help people build livable healthy habits for the long term and manage the dietary-induced side effects often felt while taking chronic weight management medications, such as glucagon-like peptide-1s (GLP-1s). CEO and Co-founder of Sequence stated in the press release that pairing behavior change with medically appropriate clinical solutions is more powerful and more sustainable than clinical alone. So it is likely that we will see WW offering semaglutide in the future
Bacteriostatic water is the preferred solvent for most research peptides because its 0.9% benzyl alcohol content inhibits microbial growth and extends usable shelf life
Jiang L, Wang J, Wang K, Wang H, Wu Q, Yang C, et al
Track small wins every day and reinforce positive behaviors over time
The subcutaneous injection is given once weekly and the tablet is administered once daily
Male: Potential benefit for varicocele-related damage and testicular inflammation
